Search results
1. NAME OF THE MEDICINAL PRODUCT. Bonviva 150 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each film-coated tablet contains 150 mg ibandronic acid (as sodium monohydrate). Excipients with known effect: Contains 154.6 mg anhydrous lactose (equivalent to 162.75 mg lactose monohydrate).
Bonviva is a medicine that contains the active substance ibandronic acid. It is available as tablets (150 mg) and as a solution for injection in a prefilled syringe (3 mg).
SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. Bonviva 150 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each film-coated tablet contains 150 mg ibandronic acid (as ibandronic sodium monohydrate). Excipients: Contains 162.75 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3.
Bonviva 150 mg is indicated for the treatment of postmenopausal osteoporosis, to reduce the risk of fractures. Osteoporosis may be confirmed by the finding of low bone mass (T score <
It contains the active substance ibandronic acid. Bonviva may reverse bone loss by stopping more loss of bone and increasing bone mass in most women who take it, even though they won’t be able to see or feel a difference. Bonviva may help lower the chances of breaking bones (fractures).
Bonviva - działanie, wskazania, dawkowanie, przeciwwskazania, interakcje, refundacja, cena. Lek z grupy bisfosfonianów hamujący resorpcję kości, stosowany w leczeniu osteoporozy.
W dwuletnim podstawowym badaniu przeprowadzonym u kobiet po menopauzie z osteoporozą (BM16550) ogólny profil bezpieczeństwa produktu Bonviva 3 mg podawanego dożylnie raz na 3 miesiące i doustnego kwasu ibandronowego 2,5 mg raz na dobę był podobny.
